Becton, Dickinson and Company (BDX)
| Market Cap | 54.18B +0.5% |
| Revenue (ttm) | 22.48B +18.5% |
| Net Income | 942.00M -40.6% |
| EPS | 3.33 -39.2% |
| Shares Out | 272.39M |
| PE Ratio | 59.72 |
| Forward PE | 15.04 |
| Dividend | $4.20 (2.11%) |
| Ex-Dividend Date | Sep 9, 2026 |
| Volume | 1,304,246 |
| Open | 199.18 |
| Previous Close | 200.42 |
| Day's Range | 197.15 - 200.42 |
| 52-Week Range | 140.11 - 213.08 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 195.57 (-1.68%) |
| Earnings Date | Nov 5, 2026 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va... [Read more]
Financial Performance
In fiscal year 2025, BDX's revenue was $21.84 billion, an increase of 8.24% compared to the previous year's $20.18 billion. Earnings were $1.68 billion, a decrease of -1.58%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $195.57, which is a decrease of -1.68% from the latest price.
News
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio we...
BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirt...
Becton Dickinson initiated with an Underweight at Barclays (yesterday)
Barclays analyst Christopher Pasquale last night initiated coverage of Becton Dickinson (BDX) with an Underweight rating and $165 price target The firm rolled out coverage of the medical suppliers and...
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence s...
BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn.,...
Becton Dickinson (BDX) Joins Trump Tariff Exemption Scramble with $19B Investment Plan
U.S. medical device company Becton Dickinson ($BDX) has agreed to invest $19 billion in the U.S. over several years, the company announced in a statement on Tuesday. In return, the…
Becton Dickinson to invest $3B to expand domestic manufacturing
Becton Dickinson (BDX) announced a partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by c...
BD Appoints Ferass Abuzaina as Worldwide President of Surgery
FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worl...
Becton Dickinson to invest $19 billion in US
Becton Dickinson plans to invest $19 billion in the US over several years, including $3 billion to expand domestic manufacturing, as part of an agreement with the government to strengthen the su...
BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
Agreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S....
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing
American medical technology company Becton Dickinson has agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, President Donald Trump said on Mo...
BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
Generations of Utah employees have helped ensure the reliable supply of essential medical devices that clinicians use every day to care for patients around the world SANDY, Utah, Sept. 29, 2026 /PRNew...
Becton Dickinson names Arthur Hu as Chief Information and Digital Officer
Becton, Dickinson and Company (BDX) announced that Arthur Hu has been named executive vice president and chief information and digital officer, effective September 30. Hu brings more than 25 years…
Arthur Hu to Join BD as Chief Information and Digital Officer
FRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named ex...
BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medicatio...
Becton, Dickinson and Company Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strong growth from focused platforms, ongoing margin expansion, and disciplined pricing. Key headwinds from Alaris, vaccines, and China are expected to ease, while innovation and capital allocation remain priorities. More strategic details and new product updates will be shared at the December Analyst Day.
3 Dividend Stocks From a Value Pro
In a rocky market, dividend stocks with generous yields and solid growth prospects may be just what your portfolio needs—if you can find them.
Becton Dickinson price target raised to $200 from $185 at BofA
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $200 from $185 and keeps a Neutral rating on the shares after having hosted investors at…
Becton Dickinson announces STANCE clinical trial enrollment milestone
Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE Scaffold in breast revision surg...
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contr...
BD to Present at Wells Fargo 21st Annual Healthcare Conference
FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo...
Becton Dickinson names Gary Sorsher as Chief Quality Officer
Becton Dickinson (BDX) announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Most recently, he served as chief quality officer at Edward...
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named execut...
Becton Dickinson completes enrollment in PREVENT trial
Becton Dickinson (BDX) announced the completion of enrollment in the PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias. Following completion of the primary endpoin...
Becton Dickinson price target raised to $208 from $204 at Citi
Citi raised the firm’s price target on Becton Dickinson (BDX) to $208 from $204 and keeps a Buy rating on the shares. The firm is more optimistic on the medical…